Genomics, Pharmaceutical R&D & Healthcare: Are we there yet?

Wilmington, DE, 26th November 2014 – As various genomics initiatives have promised to revolutionize healthcare for over 20 years, it is important to ask whether these have had the impact they were expected to make, and how we might take greater advantage of the technology available.

The Pistoia Alliance, a global, not-for-profit alliance of life science companies, vendors, publishers, and academic groups that work together to lower barriers to innovation in R&D, is hosting a ‘Pistoia Alliance Debates’ webinar which will look at whether the economic, technical and regulatory barriers have been addressed, and how to overcome any that may remain.

The webinar will see Gordon Baxter, CSO at Instem, chair a panel comprised of experts in the field including Abel Ureta-Vidal, CEO at Eagle Genomics, Fiona Nielsen, CEO at DNA Digest, Dan Housman, Director at ConvergeHealth by Deloitte, and Etzard Stolte, former CIO of the Jackson Laboratory.

As well as exploring the remaining obstacles to greater adoption of genomics technology in healthcare, the panel will look at the success of recent genomics initiatives, the impact they have had, and will consider what future genomic innovation may bring to the industry. Following the discussion, webinar attendees will be able to ask questions of the panel.

Richard Holland, Executive Director Operations at the Pistoia Alliance, said: “The genomics revolution has long heralded a number of advantages for the life sciences industry, and while some of these have become reality, others have yet to see mainstream adoption. Understanding why this happened will be crucial to making further progress in this area, and through this debate we plan to highlight future opportunities for the Pistoia Alliance to support the life sciences industry in improving its ability to develop new approaches and techniques.”

Posted in Pistoia Alliance News.

Leave a Reply

Your email address will not be published. Required fields are marked *